Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Inclusion Criteria: * Female or male subjects, 18 to 65 years of age * Have body mass index (BMI) ≥ 30 kg/m2 and ≤ 45 kg/m2 for subjects with uncomplicated obesity, and BMI of ≥ 27 kg/m2 and ≤ 45 kg/m2 for subjects with obesity and dyslipidemia and/or controlled hypertension * Non-smoker and no use of tobacco or nicotine products for at least 6 months prior to screening * Normotensive (systolic ≤140 mm Hg; diastolic ≤90 mm Hg). Anti-hypertensive medications are allowed with the exception of adrenergic blockers and clonidine. Medical regimen must be stable for at least 6 weeks prior to randomization * Triglycerides \<400 mg/dL. Medications for treatment of dyslipidemia are allowed with the exception of cholestyramine and cholestypol as long as medical regimen has been stable for at least 6 weeks prior to randomization * No clinically significant laboratory abnormalities * Negative urine drug screen * Negative serum pregnancy test in women of child-bearing potential * Women of child-bearing potential must be non-lactating, and agree to use acceptable contraception throughout the study period and for 30 days after discontinuation of study drug * Able to comply with all required study procedures and schedule * Able to speak and read English * Willing and able to give written informed consent Exclusion Criteria: * Obesity of known endocrine or genetic origin (e.g., untreated hypothyroidism, Cushing's syndrome, polycystic ovary syndrome) * Serious medical condition * History of malignancy within the previous 5 years, with exception of non-melanoma skin cancer or surgically cured cervical cancer. * History of suicide attempt or serious psychiatric illness * History of Major Depressive Disorder within the past 2 years * In need of medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months prior to randomization * Type I or Type II diabetes * History of alcohol or drug abuse or dependence as determined by the Investigator within 1 year prior to randomization * History of surgical or device (e.g. gastric banding) intervention for obesity * History of seizures or predisposition to seizures * History of hypersensitivity to sulfonamides ("sulfa"), bupropion, or zonisamide * History of treatment with bupropion SR (Wellbutrin, Zyban) or zonisamide (Zonegran) within previous 12 months * History of nephrolithiasis (renal calculi) * Loss or gain of more than 4.0 kg within 3 months prior to randomization * Women of child bearing potential not adhering to a medically acceptable form of contraception * Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug